Dcf Advisers, LLC Ovid Therapeutics Inc. Transaction History

Dcf Advisers, LLC

$242 Million
Q3 2024

A detailed history of Dcf Advisers, LLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Dcf Advisers, LLC holds 14,750 shares of OVID stock, worth $14,307. This represents 0.01% of its overall portfolio holdings.

Number of Shares

14,750

Previous 41,750 64.67%

Holding current value

$14,307

Previous $32,000 46.88%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.75 - $1.3 $20,250 - $35,100	-27,000 Reduced 64.67%	14,750 $17,000
Q2 2024 Aug 12, 2024	BUY	$0.7 - $3.34 $15,413 - $73,546	22,020 Added 111.61%	41,750 $32,000
Q1 2024 May 15, 2024	BUY	$2.72 - $4.04 $2,720 - $4,040	1,000 Added 5.34%	19,730 $60,000
Q4 2023 Feb 13, 2024	SELL	$2.98 - $3.78 $34,866 - $44,226	-11,700 Reduced 38.45%	18,730 $60,000
Q3 2023 Nov 13, 2023	SELL	$3.23 - $3.97 $110,898 - $136,305	-34,334 Reduced 53.01%	30,430 $116,000
Q2 2023 Aug 09, 2023	SELL	$2.53 - $3.89 $8,855 - $13,615	-3,500 Reduced 5.13%	64,764 $212,000
Q1 2023 May 15, 2023	SELL	$1.88 - $2.85 $3,760 - $5,700	-2,000 Reduced 2.85%	68,264 $176,000
Q4 2022 Feb 13, 2023	SELL	$1.43 - $1.89 $132,184 - $174,705	-92,437 Reduced 56.81%	70,264 $130,000
Q3 2022 Nov 14, 2022	BUY	$1.84 - $2.26 $38,640 - $47,459	21,000 Added 14.82%	162,701 $299,000
Q3 2021 Nov 15, 2021	BUY	$3.31 - $4.04 $6,620 - $8,080	2,000 Added 1.43%	141,701 $476,000
Q2 2021 Aug 13, 2021	BUY	$3.3 - $4.49 $101,310 - $137,843	30,700 Added 28.16%	139,701 $546,000
Q1 2021 May 12, 2021	BUY	$2.42 - $4.47 $263,782 - $487,234	109,001 New	109,001 $438,000

Others Institutions Holding OVID

# of Institutions

Shares Held

39M

Call Options Held

37.4K

Put Options Held

500

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $68.3M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.

Account